Travere Therapeutics News and Activities
Presence
Travere Therapeutics develops and sells medicines for rare kidney and metabolic diseases. Its products and support services help patients, doctors, and specialty care providers in the United States and other markets.
Travere Therapeutics products and services overview:
- Rare disease drugs
- Kidney disease therapies
- Metabolic disease therapies
- Prescription medicines
- Patient support services
Revenue: ~$250 million
Employees: 450
Headquarters: San Diego, United States (USA)
Travere Therapeutics is one of the...
Travere Therapeutics is a company listed under the stock ticker TVTX (US).
Executives
View the org chart displaying its 34 main executives
Most searched biographies at Travere Therapeutics
- Eric Dube, Director, President and Chief Executive Officer
- Ron Squarer, Director
- Roy Baynes, Director
Popular executive movements at Travere Therapeutics
- Sandra Calvin, Chief Accounting Officer and Principal Accounting Officer, will retire in Feb. 2027 (posted on July 12 2026).
- William Rote, who is Chief Research Officer will soon leave the company (posted on June 17 2026).
- Jula Inrig, who was Chief Medical Officer, is promoted to Executive Vice President, Head of Research, Development and Chief Medical Officer (posted on June 17 2026).
Create your alert
to follow the executive moves at Travere Therapeutics.
Biotechnology
Travere Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by Travere Therapeutics
- Travere Therapeutics Provides Corporate Update and 2025 Outlook | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at Upcoming Investor Conferences | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Proposed Public Offering of Common Stock | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at Upcoming Investor Conferences | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Third Quarter 2024 Financial Results | Travere Therapeutics, Inc.
- Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 | Travere Therapeutics, Inc.
- View more press releases Close
Social media about Travere Therapeutics
- Travere Therapeutics on Wikipedia, Google News & Yahoo Finance
- Travere Therapeutics on LinkedIn, X (Twitter) & YouTube
